This study is looking at the DNA of people with breast cancer who received bevacizumab. Researchers want to find changes in your DNA that might explain why some people develop high blood pressure (hypertension) when taking bevacizumab, while others do not. They are analyzing your germline DNA (DNA you inherit from your parents) to find specific genetic differences. The goal is to identify biomarkers, which are biological signs, that could predict who is at risk for developing hypertension from bevacizumab. This study is observational, meaning researchers are looking at existing information rather than giving new treatments, and aims to enroll 354 participants. The study is currently unclear on its recruitment status.

Study design

This is an observational study planning to include 354 participants. Researchers are analyzing previously collected DNA samples.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, identification of rare coding variants, is measured at Baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.